Tamás Resál, Péter Bacsur, Csilla Keresztes, Anita Bálint, Renáta Bor, Anna Fábián, Bernadett Farkas, Kostas Katsanos, George Michalopoylos, Davide Giuseppe Ribaldone, Mohamed Attauabi, Mirabella Zhao, Hadar Amir Barak, Henit Yanai, Cristina Bezzio, Antonio Rispo, Fabiana Castiglione, Ariella Bar-Gil Shitrit, Daniela Pugliese, Alessandro Armuzzi, Edoardo Vincenzo Savarino, Martin Kolar, Milan Lukáš, Elena Chashkova, Rafał Filip, Aurore Rozieres, Stéphane Nancey, Željko Krznarić, Eszter Schäfer, Szamosi, Patrícia Sarlós, Matej Franko, David Drobne, Oleg V Knyazev, Anna V Kagramanova, Jimmy Limdi, Panu Wetwittayakhlang, Peter L Lakatos, Nitsan Maharshak, Lian Bannon, Tibor Nyári, Zoltán Szepes, Klaudia Farkas, Tamás Molnár
BACKGROUND AND AIMS: Tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB could be an option in the treatment of acute severe ulcerative colitis (ASUC). We aimed to investigate efficacy and safety of TFB in moderate-to-severe colitis and ASUC. METHODS: This retrospective, international cohort study enrolling UC patients with ≥6-week follow-up period was conducted from February 1 to July 31, 2022...
August 5, 2023: Inflammatory Bowel Diseases